The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Safety 77

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Safety 74

Safety Dermatology Clinic Therapy 74

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. and Novartis Pharmaceuticals).

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

APRIL 4, 2024

The sBLA in moderate-to-severe HS is supported by data from the Phase 3 BE HEARD I and BE HEARD II studies where Bimzelx demonstrated clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response-50 (HiSCR50) vs. placebo at Week 16, the primary endpoint. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Kim Gallo Esthetics

FEBRUARY 27, 2024

From futuristic at-home devices to clinics equipped with state-of-the-art machinery, technology has placed the tools for radiant skin in the hands of the many. The accessibility of tools and treatments prompts questions about their efficacy and safety, reminding us to trust professionals for guidance and comprehensive understanding.

Skincare 314

Skincare Esthetician Skincare Routine Chemical Peels 314

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

The Dermatology Digest

APRIL 17, 2024

Patient enrollment is now complete in Celldex’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

JUNE 14, 2024

ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile. ICP-332 showed better efficacy profile across different classes and mechanisms of action of therapies for the treatment of AD patients although this was not a head-to-head study.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium.

Safety 36

Safety Therapy Dermatology Injections 36

New Age Spa Institute

DECEMBER 19, 2023

To Qualify for an Massage Therapy License, what’s needed? Massage Therapy License candidates need a high school diploma or GED and must complete fingerprints and a criminal background check. How To Start a Massage Therapist Career What happens after completing your massage therapy program and obtaining your license?

Private Practice 40

Private Practice Ethics Therapy Education 40

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Lower levels of hBD-2 were observed with clinical response and indicate inhibition of the IL-17/IL-23 axis. and IGA 0 (clear skin) of 45.2%. and Janssen Biotech, Inc.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

JULY 10, 2024

The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

FEBRUARY 6, 2024

The sNDA is supported by two clinical phase I studies investigating the safety of the application of three tubes of Ameluz. Further to a Type A meeting with the FDA in 2021, an additional safety trial with 100 patients receiving PDT with three tubes of Ameluz was conducted.

Safety 28

Safety Office Therapy Ingredients 28

The Dermatology Digest

MARCH 9, 2024

Apremilast (Otzela, Amgen) can improve symptoms in patients with moderate to severe palmoplantar pustulosis who had an inadequate response to topical therapy, according to a late-breaking Phase 3 study presented at the annual meeting of the American Academy of Dermatology in San Diego, CA.

Safety 36

Safety Dermatology Therapy Clinic 36

AAAMS

MAY 9, 2024

These programs usually combine theoretical knowledge with hands-on clinical experience to ensure that nurses are skilled in delivering safe and effective aesthetic treatments. Nurses were first taught the importance of maintaining a clean and sterile environment, with safety being the top priority.

Training 52

Training Ethics Technology Injections 52

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

New Age Spa Institute

JUNE 13, 2024

Each state has its own requirements for training programs and licensing exams, so it’s important to check with the specific state board of esthetics, cosmetology, massage therapy, and nail technology for detailed regulations and any updates. Business Educations is included in all licensure and certification programs!

Continuing Education 52

Continuing Education Continuous Education Education Esthetics 52

The Dermatology Digest

FEBRUARY 13, 2024

EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds that is currently in the advanced stages of clinical development. The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0 days for Santyl.

Safety 36

Safety Marketing Office Clinic 36

Aesthetics Advisor

AUGUST 15, 2023

Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement. Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. Click here to buy Theracurmin HP by Integrative Therapeutics (Amazon) 3.

Therapy 69

Therapy Safety Medical Diet 69

Eminence Organics

FEBRUARY 27, 2024

It's time to explore the latest in wellness: salt halotherapy (or salt therapy). Along with these newer therapies, we'll also discuss scientifically proven salt treatments, like salt scrubs, to give you a comprehensive view. Improved Circulation: There are suggestions that salt therapy can enhance blood circulation.

Treatments 59

Treatments Therapy Training Exfoliation 59

The Dermatology Digest

OCTOBER 5, 2023

Barr, MD, dual board-certified integrative dermatologist, certified somatic trauma therapy practitioner, Somatic Skin Science, Seattle, Washington. “It The DNA Connection Deep in our DNA, there’s a primordial theme of slowing down, connection, and safety, said Dr. Barr. I’m sure you’ve experienced this in your clinic.

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

JANUARY 10, 2024

Positive clinical data from the Phase 1b trial were announced in October 2023. The trial was a 16-week open-label study assessing the safety, tolerability, pharmacokinetics, and exploratory efficacy of once-daily topical VYN201 in 29 patients with a clinical diagnosis of active nonsegmental vitiligo, in three dose cohorts (0.5%, 1.0%

Clinic 36

Clinic Safety Dermatology Treatments 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Recommend proactive therapy with topical corticosteroids or topical calcineurin inhibitors for patients with a relapsing course of AD. Urge consideration for once-daily dosing of topical medications.

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

The Dermatology Digest

NOVEMBER 1, 2021

Cordoro, MD, and Carmel Aghdasi, BA Data presented at the Society for Pediatric Dermatology: 2021 Annual Meeting is helping to advance knowledge on epidemiology, clinical features, comorbidities, and evolving treatment patterns for pediatric psoriasis. With Kelly M. UCSF Yearlong Inquiry Program supported this program.

Document 36

Document Therapy Safety Clinic 36

The Dermatology Digest

NOVEMBER 1, 2021

Cordoro, MD, and Carmel Aghdasi, BA Data presented at the Society for Pediatric Dermatology: 2021 Annual Meeting is helping to advance knowledge on epidemiology, clinical features, comorbidities, and evolving treatment patterns for pediatric psoriasis. With Kelly M. UCSF Yearlong Inquiry Program supported this program.

Document 36

Document Therapy Safety Clinic 36

Northern Colorado Advanced Aesthetics Academy

JANUARY 27, 2022

These individuals are responsible for providing accurate and consistent treatment to patients, taking great care that safety measures are in place during the treatments. It's also worth noting that aesthetic laser technicians need extensive knowledge of advanced aesthetics, medical and laser safety, and medical terminology.

Private Practice 36

Private Practice Safety Training Esthetics 36

First Derm

JANUARY 16, 2024

Patient Safety and Success : Prioritizing skin cancer screening helps in safeguarding patient health, significantly enhancing the safety and success rates of cosmetic procedures. Compromised surgical outcomes: Performing cosmetic procedures on skin with undetected cancer can compromise the safety and effectiveness of the surgery.

Surgery 59

Surgery Scarring Safety Treatments 59